ARA-290 10mg

$79.00Ships by USPS Priority Mail to US addresses. Free shipping on orders of $150 or more, otherwise a flat $12.

ARA-290 (cibinetide), a peptide engineered from erythropoietin to act at the innate repair receptor without EPO’s effect on red blood cells. Studied in nerve-fiber research. Lyophilized powder. For research use only.

Availability: Available for pre-order

SKU: ARA-290-10mg-ER Category:
Ships as lyophilized powder, not reconstituted

Research at a Glance
  • What it is: A peptide engineered from erythropoietin to act at the innate repair receptor without EPO’s effect on red blood cells.
  • Research areas: sarcoidosis-associated small fiber neuropathy in three placebo-controlled human trials, smaller human trials in type 2 diabetes and diabetic eye disease, plus mechanism work in nerve-injury, inflammation and wound-healing research models.
  • Evidence level: Real human trial data exists, all of it small and short, and most of it in one rare-disease population. ClinicalTrials.gov lists no trial beyond phase 2.
  • The short version: ARA-290 has real, published human trial data behind it, which is genuinely uncommon in this category. That data is narrow, small groups followed for four to twelve weeks, mostly one disease population, and a development program that never reached a phase 3 trial.

Read the research →

What it is

ARA-290 is a synthetic peptide made of 11 amino acids. Its generic drug name is cibinetide. It copies the outer face of one region of erythropoietin (EPO), called helix B. It was first described in 2008 by a team led by Michael Brines and Anthony Cerami.

Specs at a glance. Reference values for the compound named on the label, from PubChem or KEGG. They describe the compound, not a measurement of the vial you receive. Molecular weight is the free base (the peptide alone, without a salt). Synthetic peptides are usually supplied as a salt such as acetate or TFA, and the salt in this vial has not been confirmed.

Compound ARA-290 (cibinetide)
Sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa)
Molecular formula C51H84N16O21
Molecular weight 1257.3 g/mol (average, free base)
CAS number 1208243-50-8
Reference record PubChem CID 91810664
Form Lyophilized (freeze-dried) powder in one sealed vial
Vial size 10 mg per vial
Storage (dry powder) -20°C or colder, long term. Keep the vial sealed and away from light.
Lab report No lab report on file for this compound. All lab reports →

What the evidence is

ARA-290 has been given to people in a handful of small trials, each four to twelve weeks long, most of them in adults with nerve damage linked to sarcoidosis. The early work behind it was in rodents. No phase 3 trial is registered.

Study Type Who or what What was given What it measured What it found
Swartjes et al., Anesthesiology, 2011 Animal Rats and mice with an injured leg nerve, including mice bred without the CD131 receptor 30 µg/kg, five doses two days apart, then once a week Sensitivity to touch and cold Lower sensitivity in treated rats for up to 15 weeks. No effect in mice without CD131
Heij et al., Molecular Medicine, 2012 Human, randomized, double-blind, placebo-controlled pilot 22 adults with sarcoidosis and small fiber neuropathy symptoms 2 mg three times a week for 4 weeks A neuropathy symptom score, pain, fatigue, mood and quality of life The symptom score improved more than placebo. Pain and fatigue improved about equally in both groups. No change in mood
Dahan et al., Molecular Medicine, 2013 Human, blinded, placebo-controlled 38 adults with sarcoidosis and small nerve fiber loss (21 on ARA-290, 17 on placebo) 4 mg daily for 28 days Neuropathy symptoms, nerve fiber density in the cornea, a 6-minute walk test Improvement reported on symptoms, corneal nerve fiber density and walk distance
Brines et al., Molecular Medicine, 2015 Human, phase 2, placebo-controlled Adults with type 2 diabetes and painful neuropathy 4 mg daily for 28 days, then one month of follow-up HbA1c, blood lipids, neuropathy symptoms, corneal nerve fiber density HbA1c, lipids and symptoms improved. Nerve fiber density rose only in the subgroup with the lowest starting density
Culver et al., Investigative Ophthalmology & Visual Science, 2017 Human, phase 2b, randomized, placebo-controlled 64 adults with sarcoidosis-related small nerve fiber loss and nerve pain 1, 4 or 8 mg a day for 28 days Main measure: corneal nerve fiber area. Also skin nerve fibers, pain and a 6-minute walk test Nerve fiber area rose more than placebo at 4 mg only. The 1 mg and 8 mg groups did not reach significance. Pain improved in every group, placebo included
Lois et al., Journal of Clinical Medicine, 2020 Human, phase 2, single group, no placebo 9 adults with diabetic macular edema (swelling at the back of the eye), 8 finished 4 mg a day for 12 weeks Visual acuity, retinal thickness, retinal sensitivity, tear production No average improvement in vision, retinal thickness, retinal sensitivity or tears. A vision-questionnaire score improved

Last reviewed 2026-09-24. Staff of Araim Pharmaceuticals, the company developing cibinetide, are authors on the 2013, 2015, 2017 and 2020 trials. More on the mechanism, and what none of it establishes, is on the full research summary →

Storage and shipping

This product is on pre-order. It ships as lyophilized powder in a sealed vial. Store the powder frozen at -20°C. US addresses only. Shipping costs and cutoff times →

Questions about ARA-290

Is ARA-290 the same thing as cibinetide?

Yes. Cibinetide is the generic drug name (INN and USAN) for ARA-290. Papers also call it ARA 290, ARA290 and pHBSP, short for pyroglutamate helix B surface peptide.

Is there human data?

Yes, but it is small. The five patient trials above enrolled between 9 and 64 people and ran four to twelve weeks. The largest found a difference from placebo at one of three doses, and the diabetic eye trial found no average change in vision.

Is ARA-290 an approved drug?

We found no approval anywhere. Its developer announced an FDA orphan drug designation in 2016, which marks a drug in development, not an approved one, and ClinicalTrials.gov lists no cibinetide trial past phase 2. Etched Research sells ARA-290 as a research compound for laboratory use only. It is not for human use.

Is there a lab report for ARA-290?

Not yet. No independent lab report is on file for this compound. When one is, it will be listed on the lab reference page.

Shipping, eligibility and what comes in the box: store FAQ →

For research use only. Not for human consumption.

Scroll to Top